5 amino 1mq safety human data Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice 5-Amino-1MQ Benefits, Safety, and Uses

Groups with limited or no safety data Published human trials with AOD-9604 enrolled adults with obesity (BMI 30-45 kg/m^2), generally aged 18-65

5-Amino-1MQ targets the enzyme, which controls fat metabolism

Protocol, Administration and Cost MIC is given intramuscularly, typically into the deltoid or gluteal muscle, most commonly weekly, sometimes twice weekly early in a programme

Results vary by individual and treatment adherence

Pregnant patients with B deficiency should be closely monitored and treated appropriately to ensure healthy outcomes

While theres no direct evidence suggesting harm in using Semaglutide and AOD 9604 together, theres limited research on their combined efficacy